Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Joseph O. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses a session he co-chaired on the thorny questions of how best to improve cancer care.
Craig Earle, MD, of Canada’s Institute for Clinical Evaluative Sciences, summarizes abstracts discussed in a ticketed session that he co-chaired on this key topic. (Abstracts 173, 174, 175)
Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
